HPV vaccine reduces cancer risk in young men—large real-world study confirms protection.

HPV vaccine reduces cancer risk in young men—large real-world study confirms protection.

While the HPV vaccine has been well-established in women, evidence for cancer protection in males has been more limited. This large retrospective cohort study found that the 9-valent HPV vaccine was associated with significantly lower risk of HPV-related cancers in adolescent males and young men.

HPV causes several cancers in males including oropharyngeal, anal, and penile cancers. Real-world evidence of vaccine effectiveness in this population strengthens the case for universal vaccination programs and may increase uptake in males where vaccination rates have historically been lower.

This adds to the compelling evidence base supporting HPV vaccination as a public health strategy for cancer prevention across all sexes.

Key Findings

• 9-valent HPV vaccine associated with lower risk of HPV-related cancers in adolescent males and young men
• Large retrospective cohort study design
• HPV causes oropharyngeal, anal, and penile cancers in males
• Vaccine effectiveness confirmed in real-world (non-trial) population
• Supports universal HPV vaccination programs regardless of sex

Implications

This finding should strengthen public health messaging around HPV vaccination in males and support universal vaccination policies. Insurance coverage and access programs for male HPV vaccination may need strengthening. Clinicians should actively recommend the vaccine for eligible males.

Caveats

Meeting/news abstract with limited methodological detail; abstract-only. Retrospective cohort—potential confounders. Follow-up duration relative to cancer development timeline matters. Specific cancer types most strongly protected not detailed in this abstract.

Source: MedPage Hematology/Oncology — 2026-04-10